Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5697
-0.0293 (-4.89%)
At close: Sep 9, 2026, 4:00 PM EDT
0.5441
-0.0256 (-4.49%)
After-hours: Sep 9, 2026, 7:34 PM EDT
Pasithea Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
19.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 15.06K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| Lipocine | 1.57M |
| Longeveron | 1.19M |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
KTTA News
- 10 hours ago - Pasithea Therapeutics Transcript: AGM 2026 - Transcripts
- 12 hours ago - Pasithea Therapeutics Slides: Corporate presentation - Filings
- 6 days ago - Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - GlobeNewsWire
- 26 days ago - Pasithea Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Pasithea Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Pasithea Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Pasithea Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Pasithea Therapeutics Slides: Corporate presentation - Filings